Twist Bioscience's RSI reading indicates heavy selling is exhausting itself, coinciding with analysts raising earnings estimates.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Twist Bioscience's RSI reading indicates heavy selling is exhausting itself, coinciding with analysts raising earnings estimates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Twist Bioscience
Biotechnology company
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.
Coverage
Newest first; wire copies grouped- ZacksAfter Plunging 33.8% in 4 Weeks, Here's Why the Trend Might Reverse for Twist Bioscience (TWST) Twist Bioscience (TWST) has been beaten down lately with too much selling pressure. While the stock has